Payment overview · 2025
General Payments
$534.69
29 reported records · 12 companies
Healthcare provider profile · identity verified
Eric W Smith, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SHREVEPORT, LA · NPI 1417910720
Verified facts
What the public records show
CMS Open Payments records show Eric W Smith, M.D. received $534.69 in general payments during 2025 across 29 reported records.
Dexcom, Inc. accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $111.36 | 20.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $103.91 | 19.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $103.73 | 19.4% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.44 | 8.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.66 | 7.0% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $26.07 | 4.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.18 | 4.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.41 | 4.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.61 | 3.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.63 | 2.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.11 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.58 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $534.69 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $111.36 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $103.73 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $103.73 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $72.65 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.44 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $31.26 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.11 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 108 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
108 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 580 | 162 |
| Atorvastatin Calcium | Atorvastatin Calcium | 563 | 169 |
| Alprazolam | Alprazolam | 386 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 383 | 110 |
| Losartan Potassium | Losartan Potassium | 329 | 105 |
| Hydrochlorothiazide | Hydrochlorothiazide | 278 | 79 |
| Gabapentin | Gabapentin | 274 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 84 |
| Lisinopril | Lisinopril | 242 | 68 |
| Metformin Hcl | Metformin Hcl | 225 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 209 | 54 |
| Potassium Chloride | Potassium Chloride | 192 | 59 |
| Omeprazole | Omeprazole | 171 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 160 | 44 |
| Trazodone Hcl | Trazodone Hcl | 159 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 47 |
| Simvastatin | Simvastatin | 151 | 46 |
| Ozempic | Semaglutide | 141 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 29 |
| Glimepiride | Glimepiride | 137 | 38 |
| Furosemide | Furosemide | 135 | 48 |
| Meloxicam | Meloxicam | 134 | 28 |
| Eliquis | Apixaban | 126 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 34 |
| Farxiga | Dapagliflozin Propanediol | 108 | 27 |
| Montelukast Sodium | Montelukast Sodium | 108 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 30 |
| Azithromycin | Azithromycin | 94 | 82 |
| Carvedilol | Carvedilol | 94 | 25 |
| Atenolol | Atenolol | 91 | 27 |
| Sertraline Hcl | Sertraline Hcl | 89 | 25 |
| Temazepam | Temazepam | 87 | 20 |
| Tramadol Hcl | Tramadol Hcl | 85 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 23 |
| Methylprednisolone | Methylprednisolone | 82 | 65 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 17 |
| Mounjaro | Tirzepatide | 74 | 14 |
| Clonazepam | Clonazepam | 73 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 18 |
| Ezetimibe | Ezetimibe | 68 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 46 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 63 | 16 |
| Synthroid | Levothyroxine Sodium | 62 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 13 |
| Donepezil Hcl | Donepezil Hcl | 57 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 15 |
| Celecoxib | Celecoxib | 52 | 17 |
| Jardiance | Empagliflozin | 52 | 16 |
| Allopurinol | Allopurinol | 49 | 13 |
| Januvia | Sitagliptin Phosphate | 49 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 12 |
| Estradiol | Estradiol | 46 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 13 |
| Methocarbamol | Methocarbamol | 45 | 15 |
| Nifedipine Er | Nifedipine | 43 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 12 |
| Diazepam | Diazepam | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 12 |
| Fluconazole | Fluconazole | 38 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 11 |
| Bumetanide | Bumetanide | 35 | suppressed |
| Prednisone | Prednisone | 35 | 19 |
| Finasteride | Finasteride | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 13 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 23 |
| Pregabalin | Pregabalin | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Glipizide | Glipizide | 26 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 15 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Colchicine | Colchicine | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $534.69 · 29 records | Dexcom, Inc. | AIRSUPRA, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Korlym, MOUNJARO, Ozempic, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error